Agenus Enters into Clinical Collaboration with Nelum for Zalifrelimab Combination

LEXINGTON, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it has entered into a clinical collaboration with Nelum Corp. to evaluate the safety and efficacy of zalifrelimab, Agenus’ anti-CTLA-4 antibody, in combination with NLM-001, Nelum’s small molecule hedgehog inhibitor, and chemotherapy for first-line advanced pancreatic cancer. “This collaboration with Nelum is an exciting next step in our partnership strategy to broaden combinations and indications with our late stage checkpoint antibodies,” said Julie DeSander, Vice President of Business Development and Alliance Management. “Zalifrelimab, our first generation anti-CTLA-4 antibody, shows promising results alone and in combination with balstilimab, our anti-PD-1 antibody, and offers the potential to expand therapeutic benefit in novel combinations.” Nelum’s NLM-001 is a best-in-class small-molecule hedgehog inhibitor that targets cancer-associated fibroblasts. It synergizes with checkpoint inhibitors by promoting immune cell infiltration into the tumor microenvironment and increases tumor penetration of chemotherapy. NLM-001 is active and well-tolerated in patients with solid tumors, as demonstrated in a Phase I study. “NLM-001 is designed to disrupt the tumor microenvironment for increased responsiveness to checkpoint inhibition and improved delivery of chemotherapy,” said Evelio Perea, Chairman of the Board of Nelum. “We look forward to evaluating NLM-001 in combination with Agenus’ checkpoint inhibitor zalifrelimab to expand therapeutic options for patients with advanced pancreatic cancer.” Under the terms of the agreement, Agenus will supply zalifrelimab to Nelum for the combination study. Nelum will sponsor and be responsible for the conduct of the trial, which is set to begin enrolling in 1H21. About Agenus Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter. About Nelum Nelum Corp. is a US-based, clinical stage biopharmaceutical company that is developing first-in-class and best-in-class patented drugs with a focus on unmet clinical needs. Nelum’s NLM-001 is a best-in-class small molecule hedgehog inhibitor that targets cancer-associated fibroblasts. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the anticipated benefits of the Nelum collaboration, the anticipated timing of the combination trial with zalifrelimab and NLM-001, and the therapeutic potential of zalifrelimab in novel combinations. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Contact: Agenus Inc. Caroline Bafundo 212-994-8209 [email protected] View All News Contact Us Agenus Inc. [email protected] Quick Links SEC Filings Information Request Form Investor Email Alerts To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time. At Agenus Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. By providing your email address below, you are providing consent to Agenus Inc. to send you the requested Investor Email Alert updates. * Required Email Address * Investor Alert Options Investor Alert Options * News Quarterly Reports Annual Reports SEC Filings End of Day Stock Quote Events & Presentations Unsubscribe Email Alert Sign Up Confirmation Request A Meeting With Management > Agenus Inc. 3 Forbes Road Lexington, MA 02421-7305 T: +1 781.674.4400 | F: +1 781.674.4200 © 2023 Agenus Inc. All rights reserved. Privacy policy Terms and conditions of use Overview Pipeline Capabilities Publications Patients Investors Media In the News Podcast Join us Contact us

The release as fetched from its publisher. agenusbio.com ↗